Nanoformulation Strategies for Cancer Treatment provides an up-to-date review on current developments and regulatory and clinical challenges in the field of nanopharmaceuticals and the effective treatment of diverse varieties of cancer. This important reference source is ideal for biomaterials scientists and pharmaceutical scientists working in the area of cancer diagnosis and therapy. Due to the high cost of traditional cancer treatment types, researchers have increasingly looked for new ways to augment the therapeutic performance of existing drug candidates. The use of nanotechnology-based approaches have gained significant momentum, thus leading to the launch of a series of new drug products.
As nanopharmaceuticals improve the therapeutic performance of cancer therapy drugs, but also provide opportunities for site-specific drug targeting in tumors, this work is a welcomed resource on the topics discussed.
1. Cover image - p. Cover 2. Title page - p. iii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. List of contributors - p. xv 6. Section A: General consideration on cancer nanomedicines - p. xvii 7. Chapter 1. Nanomedicine for combinational anticancer drug therapeutics: Recent advances, challenges, and future perspectives - p. 3 8. Chapter 2. Market research in cancer therapeutics: New and generic product development - p. 17 9. Chapter 3. Regulatory perspectives of nanomedicines for cancer treatment - p. 29 10. Section B: Formulation technologies in cancer nanomedicines - p. 44 11. Chapter 4. Biopharmaceutical challenges in using lipid nanoparticles for oral chemotherapy - p. 53 12. Chapter 5. Polymeric nanoparticles for potential drug delivery applications in cancer - p. 65 13. Chapter 6. Lipid–polymer hybrid nanoparticles: Production, characterization and formulation of nucleic acids for cancer therapy - p. 89 14. Chapter 7. Metallic nanoparticles in drug delivery and cancer treatment - p. 107 15. Chapter 8. Liposomal nanotherapeutics in cancer treatment - p. 121 16. Chapter 9. Surface-decoration strategies in nanomedicine for cancer treatment - p. 131 17. Chapter 10. Protein-based nanomedicines as anticancer drug delivery platforms - p. 153 18. Chapter 11. Phytoactives-loaded nanocarriers for liver cancer treatment - p. 171 19. Section C: Innovative treatment strategies in cancer nanomedicines - p. 185 20. Chapter 12. Nanotechnology-assisted medical devices in cancer treatment - p. 195 21. Chapter 13. Immunotherapy as a boon in cancer treatment - p. 207 22. Chapter 14. Antibody-drug combination therapy in cancer treatment - p. 227 23. Chapter 15. Immunochemo combination therapy in cancer treatment - p. 255 24. Section D: Clinical perspectives in cancer nanomedicines - p. 270 25. Chapter 16. Formulation and biological stability of nanomedicines in cancer treatment - p. 277 26. Chapter 17. Nanotoxicology profiling of cancer nanomedicines - p. 291 27. Chapter 18. Clinical translation status of nanoformulations - p. 303 28. Section E: Regulatory perspectives in cancer nanomedicines - p. 336 29. Chapter 19. Good laboratory practice and current good manufacturing practice requirements in the development of cancer nanomedicines - p. 341 30. Chapter 20. Quality by Design approach for systematic development of nanoformulations - p. 353 31. Index - p. 365
Nanoformulation Strategies for Cancer Treatment provides an up-to-date review on current developments and regulatory and clinical challenges in the field of nanopharmaceuticals and the effective treatment of diverse varieties of cancer. This important reference source is ideal for biomaterials scientists and pharmaceutical scientists working in the area of cancer diagnosis and therapy. Due to the high cost of traditional cancer treatment types, researchers have increasingly looked for new ways to augment the therapeutic performance of existing drug candidates. The use of nanotechnology-based approaches have gained significant momentum, thus leading to the launch of a series of new drug products.
As nanopharmaceuticals improve the therapeutic performance of cancer therapy drugs, but also provide opportunities for site-specific drug targeting in tumors, this work is a welcomed resource on the topics discussed.
1. Cover image - p. Cover 2. Title page - p. iii 3. Table of Contents - p. iii 4. Copyright - p. iv 5. List of contributors - p. xv 6. Section A: General consideration on cancer nanomedicines - p. xvii 7. Chapter 1. Nanomedicine for combinational anticancer drug therapeutics: Recent advances, challenges, and future perspectives - p. 3 8. Chapter 2. Market research in cancer therapeutics: New and generic product development - p. 17 9. Chapter 3. Regulatory perspectives of nanomedicines for cancer treatment - p. 29 10. Section B: Formulation technologies in cancer nanomedicines - p. 44 11. Chapter 4. Biopharmaceutical challenges in using lipid nanoparticles for oral chemotherapy - p. 53 12. Chapter 5. Polymeric nanoparticles for potential drug delivery applications in cancer - p. 65 13. Chapter 6. Lipid–polymer hybrid nanoparticles: Production, characterization and formulation of nucleic acids for cancer therapy - p. 89 14. Chapter 7. Metallic nanoparticles in drug delivery and cancer treatment - p. 107 15. Chapter 8. Liposomal nanotherapeutics in cancer treatment - p. 121 16. Chapter 9. Surface-decoration strategies in nanomedicine for cancer treatment - p. 131 17. Chapter 10. Protein-based nanomedicines as anticancer drug delivery platforms - p. 153 18. Chapter 11. Phytoactives-loaded nanocarriers for liver cancer treatment - p. 171 19. Section C: Innovative treatment strategies in cancer nanomedicines - p. 185 20. Chapter 12. Nanotechnology-assisted medical devices in cancer treatment - p. 195 21. Chapter 13. Immunotherapy as a boon in cancer treatment - p. 207 22. Chapter 14. Antibody-drug combination therapy in cancer treatment - p. 227 23. Chapter 15. Immunochemo combination therapy in cancer treatment - p. 255 24. Section D: Clinical perspectives in cancer nanomedicines - p. 270 25. Chapter 16. Formulation and biological stability of nanomedicines in cancer treatment - p. 277 26. Chapter 17. Nanotoxicology profiling of cancer nanomedicines - p. 291 27. Chapter 18. Clinical translation status of nanoformulations - p. 303 28. Section E: Regulatory perspectives in cancer nanomedicines - p. 336 29. Chapter 19. Good laboratory practice and current good manufacturing practice requirements in the development of cancer nanomedicines - p. 341 30. Chapter 20. Quality by Design approach for systematic development of nanoformulations - p. 353 31. Index - p. 365
